Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda.

MP, Menon; H, Ddungu; KR, Mubiru; SV, Adams; J, Asea; R, Namagembe; P, Namuli; J, Kambugu; AMH, Towlerton; C, Puronen; TS, Uldrick; J, Orem; EH, Warren

doi:10.1200/go-24-00489

Public

Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda.

Shared by NobleBlocks on Apr 4, 2025 • 12:00 AM UTC

Authors:

Menon MP

Ddungu H

Mubiru KR

Abstract

Purpose Patients with diffuse large B-cell lymphoma (DLBCL) who are treated in low-resource settings have inferior outcomes compared with those in high-resource settings. Rituximab, an anti-CD20 monoclonal antibody, when combined with chemotherapy, improves overall survival (OS) for DLBCL. However, ...

Discussions